191 related articles for article (PubMed ID: 24658818)
1. The clinical significance of patients' sex in chronic lymphocytic leukemia.
Catovsky D; Wade R; Else M
Haematologica; 2014 Jun; 99(6):1088-94. PubMed ID: 24658818
[TBL] [Abstract][Full Text] [Related]
2. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
Gonzalez D; Else M; Wren D; Usai M; Buhl AM; Parker A; Oscier D; Morgan G; Catovsky D
Haematologica; 2013 Feb; 98(2):274-8. PubMed ID: 22899580
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
Oscier D; Wade R; Davis Z; Morilla A; Best G; Richards S; Else M; Matutes E; Catovsky D;
Haematologica; 2010 Oct; 95(10):1705-12. PubMed ID: 20511662
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival.
Pratt G; Thomas P; Marden N; Alexander D; Davis Z; Hussey D; Parry H; Harding S; Catovsky D; Begley J; Oscier D
Leuk Lymphoma; 2016 Oct; 57(10):2342-50. PubMed ID: 26732125
[TBL] [Abstract][Full Text] [Related]
6. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Rose-Zerilli MJ; Forster J; Parker H; Parker A; Rodríguez AE; Chaplin T; Gardiner A; Steele AJ; Collins A; Young BD; Skowronska A; Catovsky D; Stankovic T; Oscier DG; Strefford JC
Haematologica; 2014 Apr; 99(4):736-42. PubMed ID: 24584352
[TBL] [Abstract][Full Text] [Related]
7. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
8. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
9. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
10. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.
Goede V; Cramer P; Busch R; Bergmann M; Stauch M; Hopfinger G; Stilgenbauer S; Döhner H; Westermann A; Wendtner CM; Eichhorst B; Hallek M;
Haematologica; 2014 Jun; 99(6):1095-100. PubMed ID: 24584349
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Royo C; Navarro A; Pinyol M; Rozman M; Pereira A; Villamor N; Aymerich M; López C; Carrió A; Montserrat E
Haematologica; 2014 Oct; 99(10):1599-604. PubMed ID: 24972773
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.
Santacruz R; Villamor N; Aymerich M; Martínez-Trillos A; López C; Navarro A; Rozman M; Beà S; Royo C; Cazorla M; Colomer D; Giné E; Pinyol M; Puente XS; López-Otín C; Campo E; López-Guillermo A; Delgado J
Haematologica; 2014 May; 99(5):873-80. PubMed ID: 24700492
[TBL] [Abstract][Full Text] [Related]
13. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
14. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
15. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
[TBL] [Abstract][Full Text] [Related]
16. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.
Göbel M; Eisele L; Möllmann M; Hüttmann A; Johansson P; Scholtysik R; Bergmann M; Busch R; Döhner H; Hallek M; Seiler T; Stilgenbauer S; Klein-Hitpass L; Dührsen U; Dürig J
PLoS One; 2013; 8(8):e72107. PubMed ID: 24009671
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
18. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Fabris S; Pesce EA; Baldini L; Di Raimondo F; Musolino C; Di Tonno P; Di Renzo N; Molica S; Brugiatelli M; Ilariucci F; Zupo S; Matis S; Maura F; Vigna E; Angrilli F; Recchia AG; Quarta G; Iannitto E; Fragasso A; Musto P; Spriano M; Vincelli I; Vallisa D; Cortelezzi A; Mauro FR; Foà R; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2013 Jul; 88(7):539-44. PubMed ID: 23553682
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
Dearden C; Wade R; Else M; Richards S; Milligan D; Hamblin T; Catovsky D; ; ;
Blood; 2008 Feb; 111(4):1820-6. PubMed ID: 18055869
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.
Parikh SA; Rabe KG; Kay NE; Call TG; Ding W; Schwager SM; Bowen DA; Conte M; Jelinek DF; Slager SL; Shanafelt TD
Haematologica; 2014 Jan; 99(1):140-7. PubMed ID: 23911703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
